Entelexo
Early Stage
Creating a new class of drugs to address incurable autoimmune diseases
Overview
Raised: $42,565
Total Commitments ($USD)
Platform
Wefunder
Start Date
06/23/2021
Close Date
07/28/2021
Min. Goal
$20,000
Max. Goal
$1,070,000
Min. Investment
$100
Security Type
SAFE
Series
Seed
SEC Filing Type
RegCF
Valuation Cap
$15,000,000
Discount
0%
Rolling Commitments ($USD)
Status
Funded
Reporting Date
07/31/2021
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$1,252
# of Investors
120
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2021
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B
Margin
High
Capital Intensity
High
Entelexo, with a $15 million valuation cap, is raising crowdfunding on Wefunder. The company is creating drugs to address incurable autoimmune diseases. The proprietary exosome engineering platform of Entelexo targets autoimmune diseases and has been proven effective in treating multiple sclerosis. Milad Riazifar founded Entelexo in April 2020 and has raised over $1 million in previous rounds of funding. The proceeds of the current crowdfunding campaign, with a minimum goal of $50,000 and a maximum goal of $1,070,000, will be used towards preclinical testing, laboratory supplies, and a scientific advisory board. Entelexo is targeting 25 million people affected by autoimmune diseases and is working on product development and IND enabling animal studies.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$9,292 |
$0 |
|
Tax |
$23,575 |
$0 |
| ||
| ||
|
Net Income |
$-70,818 |
$0 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$305,905 |
$0 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$357,261 |
$0 |
|
Short-Term Debt |
$0 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$0 |
$0 |
Financials as of: 06/23/2021
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.